CL2007002533A1 - Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e - Google Patents

Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e

Info

Publication number
CL2007002533A1
CL2007002533A1 CL200702533A CL2007002533A CL2007002533A1 CL 2007002533 A1 CL2007002533 A1 CL 2007002533A1 CL 200702533 A CL200702533 A CL 200702533A CL 2007002533 A CL2007002533 A CL 2007002533A CL 2007002533 A1 CL2007002533 A1 CL 2007002533A1
Authority
CL
Chile
Prior art keywords
trifluorometil
composition
benzoimidazol
imidazol
phenyl
Prior art date
Application number
CL200702533A
Other languages
English (en)
Inventor
Rampurna Hashash Ah Gullapalli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of CL2007002533A1 publication Critical patent/CL2007002533A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL200702533A 2006-08-30 2007-08-30 Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e CL2007002533A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84117706P 2006-08-30 2006-08-30
US95446607P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
CL2007002533A1 true CL2007002533A1 (es) 2008-02-08

Family

ID=39027583

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702533A CL2007002533A1 (es) 2006-08-30 2007-08-30 Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e

Country Status (34)

Country Link
US (2) US8202998B2 (es)
EP (1) EP2059518B1 (es)
JP (1) JP5279712B2 (es)
KR (1) KR20090043542A (es)
CN (1) CN101516870B (es)
AT (1) ATE504584T1 (es)
AU (1) AU2007290388B2 (es)
BR (1) BRPI0716243A2 (es)
CA (1) CA2660376C (es)
CL (1) CL2007002533A1 (es)
CO (1) CO6150180A2 (es)
CY (1) CY1112187T1 (es)
DE (1) DE602007013774D1 (es)
DK (1) DK2059518T3 (es)
ES (1) ES2360968T3 (es)
GT (1) GT200900045A (es)
HK (1) HK1131613A1 (es)
HR (1) HRP20110311T1 (es)
IL (1) IL196811A (es)
JO (1) JO2702B1 (es)
MA (1) MA30711B1 (es)
MX (1) MX2009002279A (es)
MY (1) MY161829A (es)
NO (1) NO20091236L (es)
NZ (1) NZ574620A (es)
PE (2) PE20130814A1 (es)
PL (1) PL2059518T3 (es)
PT (1) PT2059518E (es)
RU (1) RU2457206C2 (es)
SI (1) SI2059518T1 (es)
TN (1) TN2009000068A1 (es)
TW (1) TW200819438A (es)
WO (1) WO2008027523A2 (es)
ZA (1) ZA200900664B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130814A1 (es) 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
AU2008251764B2 (en) * 2007-03-02 2012-09-13 Novartis Ag Solid forms of a Raf kinase inhibitor
BRPI0915106A2 (pt) * 2008-06-13 2016-02-10 Novartis Ag benzimidazóis substituídos para neurofibromatose
SI2391366T1 (sl) * 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
JP2013544845A (ja) * 2010-12-03 2013-12-19 ノバルティス アーゲー 医薬組成物
US20230000775A1 (en) * 2019-12-02 2023-01-05 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US20060189619A1 (en) 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US7731795B2 (en) 2005-12-02 2010-06-08 Clemson University Rhombohedral fluoroberyllium borate crystals and hydrothermal growth thereof for use in laser and non-linear optical applications and devices
AU2007275634B2 (en) * 2006-07-21 2011-01-20 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
RU2457206C2 (ru) 2012-07-27
MA30711B1 (fr) 2009-09-01
PT2059518E (pt) 2011-07-11
TW200819438A (en) 2008-05-01
PL2059518T3 (pl) 2011-09-30
CN101516870A (zh) 2009-08-26
US20120308651A1 (en) 2012-12-06
IL196811A0 (en) 2009-11-18
WO2008027523A3 (en) 2008-04-10
CO6150180A2 (es) 2010-04-20
SI2059518T1 (sl) 2011-06-30
MX2009002279A (es) 2009-03-20
EP2059518A2 (en) 2009-05-20
AU2007290388B2 (en) 2011-07-14
DE602007013774D1 (de) 2011-05-19
MY161829A (en) 2017-05-15
ES2360968T3 (es) 2011-06-10
RU2009111384A (ru) 2010-10-10
DK2059518T3 (da) 2011-05-16
ATE504584T1 (de) 2011-04-15
AU2007290388A1 (en) 2008-03-06
CA2660376A1 (en) 2008-03-06
TN2009000068A1 (en) 2010-08-19
GT200900045A (es) 2010-06-14
HRP20110311T1 (hr) 2011-08-31
CA2660376C (en) 2014-04-15
IL196811A (en) 2013-03-24
EP2059518B1 (en) 2011-04-06
CY1112187T1 (el) 2015-12-09
JO2702B1 (en) 2013-03-03
US8202998B2 (en) 2012-06-19
US20100168060A1 (en) 2010-07-01
NZ574620A (en) 2011-05-27
ZA200900664B (en) 2009-12-30
US8501785B2 (en) 2013-08-06
CN101516870B (zh) 2013-09-11
PE20130814A1 (es) 2013-08-08
JP5279712B2 (ja) 2013-09-04
WO2008027523A2 (en) 2008-03-06
KR20090043542A (ko) 2009-05-06
HK1131613A1 (en) 2010-01-29
BRPI0716243A2 (pt) 2013-09-03
NO20091236L (no) 2009-03-27
PE20080766A1 (es) 2008-06-15
JP2010502622A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
CL2007002533A1 (es) Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e
EA201100030A1 (ru) Пиразольные соединения 436
CL2012001391A1 (es) Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios.
BRPI1008396B8 (pt) composto de sal de tosilato de um derivado de 5-pirazolil-2-piridona, composição farmacêutica, uso e processo para preparação do dito composto
DOP2014000133A (es) Triazolopiridinas sustituidas
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
CL2015001974A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2008001815A1 (es) Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer.
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
BR112013011949A2 (pt) "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis"
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
NZ600801A (en) Substituted imidazopyridinyl-aminopyridine compounds
BR112014005190A2 (pt) composições em microcápsula compreendendo gelificantes de di-amido ajustáveis por ph
UY33452A (es) Triazolopiridinas sustituidas
BR112013026935A2 (pt) preparação de base aquosa, composição para limpeza de superfícies de materiais refratários e uso da composição
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
MA32628B1 (fr) Agents antifongiques
CL2008000797A1 (es) Composicion farmaceutica liquida que comprende una sal de 4-(2-(4-metilfenilsulfanil)fenil)piperidina seleccionada entre la sal de adicion de acido dl-lactico, glutarico, l-aspartico y glutamico; uso de dicha composicion para tratar trastornos del es
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
CL2008000673A1 (es) Compuestos derivados de aril sulfonamidas; metodo para preparar dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer de ovario, entre otras enfermedades.
AR062591A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
BRPI0519839A2 (pt) derivados do ácido 1h-indol-3-carboxìlico e seu uso como agonistas de ppar
CL2008000663A1 (es) Forma cristalina de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)triazol-4-il)benzonitrilo; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso para tratar sindrome de ovario poliquistico, cancer, entre otras enfermedades.